. 2014 Mar;11(1):63–73. doi: 10.3969/j.issn.1671-5411.2014.01.001

Table 2. Clinical parameters.

	Hypertension only									Polycystic kidney disease with hypertension
	Placebo (n = 6)			50 mg levodopa (n = 12)			100 mg levodopa (n = 8)			Placebo (n = 12)			50 mg levodopa (n = 12)			100 mg levodopa (n = 12)
	Baseline	2 h	7 day	Baseline	2 h	7 day	Baseline	2 h	7 day	Baseline	2 h	7 day	Baseline	2 h	7 day	Baseline	2 h	7 day
Age, yrs	36.8 ± 2.7			36.8 ± 1.6			36.5 ± 1.9			37.1 ± 1.9			37.4 ± 1.4			37.4 ± 1.5
BMI, kg/m²	25.5 ± 1.2			25.9 ± 1.1			23.1 ± 1.5			28.1 ± 1.3			27.1 ± 1.2			27.1 ± 1.2
MAP, mmHg	108.9 ± 1.3	106.4 ± 1.0	108.6 ± 1.2	108.2 ± 1.0	104.7 ± 1.3	104.7 ± 1.3	108.8 ± 0.8	104.8 ± 1.2	104.4 ± 1.1	107.4 ± 0.9	106.8 ± 1.0	106.7 ± 0.9	107.4 ± 0.8	104.1 ± 1.5	104.9 ± 1.0	108.0 ± 0.7	107.0 ± 0.8	104.1 ± 1.2
SBP, mmHg	136.7 ± 1.7	136.2 ± 1.1	135.8 ± 1.5	136.2 ± 1.1	132.5 ± 1.3	132.5 ± 1.3	137.5 ± 1.3	133.1 ± 1.6	133.1 ± 1.6	134.6 ± 1.0	133.8 ± 0.9	134.2 ± 1.0	135.3 ± 0.7	133.4 ± 1.0	132.8 ± 0.9	135.3 ± 0.7	135.3 ± 0.7	132.8 ± 1.0
DBP, mmHg	95.0 ± 1.3	93.3 ± 1.1	95.0 ± 1.3	94.2 ± 1.0	90.8 ± 1.4	90.8 ± 1.4	94.4 ± 0.6	90.6 ± 1.1	90.0 ± 0.9	93.8 ± 1.1	93.3 ± 1.1	92.9 ± 1.0	93.4 ± 0.9	89.4 ± 1.0	90.9 ± 1.0	94.4 ± 0.8	92.8 ± 0.9	89.7 ± 1.3
HR, beats/min	72 ± 3.2	71.3 ± 3.4	72 ± 3.4	72.7 ± 2.9	73.2 ± 2.7	72.7 ± 2.9	75 ± 2.3	73.8 ± 2.4	73.5 ± 2.5	68.5 ± 1.9	67.7 ± 1.8	68.2 ± 1.9	68.8 ± 1.5	68.9 ± 1.4	67.8 ± 1.3	68.3 ± 1.4	67.8 ± 1.3	71.1 ± 1.1
Creatinin, mg/dL	0.75 ± 0.03	N/A	0.75 ± 0.03	0.79 ± 0.03	N/A	0.82 ± 0.02	0.81 ± 0.03	N/A	0.83 ± 0.03	1.32 ± 0.04	N/A	1.32 ± 0.04	1.28 ± 0.04	N/A	1.28 ± 0.03	1.19 ± 0.03	N/A	1.18 ± 0.04
Urea, mg/dL	27.8 ± 1.0	N/A	28.3 ± 1.2	27.5 ± 1.1	N/A	27.6 ± 1.3	28.1 ± 0.9	N/A	28.6 ± 1.1	29.5 ± 0.8	N/A	29.7 ± 0.9	28.1 ± 0.9	N/A	28.4 ± 1.0	28.3 ± 0.9	N/A	28.6 ± 0.9
Ca²⁺, mg/dL	9.9 ± 0.2	N/A	9.8 ± 0.2	9.8 ± 0.1	N/A	9.8 ± 0.1	9.8 ± 0.1	N/A	9.8 ± 0.1	9.1 ± 0.1	N/A	9.0 ± 0.1	9.1 ± 0.1	N/A	9.1 ± 0.1	8.9 ± 0.1	N/A	9.1 ± 0.1
Na⁺, mEq/L	145.2 ± 1.1	N/A	145.7 ± 1.3	144.3 ± 1.0	N/A	144.7 ± 1.0	143.8 ± 0.8	N/A	143.4 ± 1.2	142.2 ± 1.2	N/A	142.5 ± 1.1	142.3 ± 0.9	N/A	142.9 ± 1.1	142.5 ± 0.9	N/A	142.6 ± 0.9
K⁺, mEq/L	4.1 ± 0.1	N/A	4.1 ± 0.2	4.3 ± 0.1	N/A	4.3 ± 0.1	4.4 ± 0.1	N/A	4.4 ± 0.2	4.0 ± 0.1	N/A	4.0 ± 0.1	4.0 ± 0.1	N/A	4.0 ± 0.1	4.0 ± 0.1	N/A	4.1 ± 0.1
Albumin, g/dL	3.6 ± 0.13	N/A	3.6 ± 0.04	3.6 ± 0.03	N/A	3.6 ± 0.02	3.6 ± 0.03	N/A	3.7 ± 0.03	3.5 ± 0.03	N/A	3.6 ± 0.03	3.5 ± 0.02	N/A	3.5 ± 0.03	3.5 ± 0.03	N/A	3.5 ± 0.03
ALT, IU/L	9.8 ± 0.9	N/A	9.9 ± 0.9	8.3 ± 0.6	N/A	8.6 ± 0.7	8.9 ± 0.6	N/A	8.9 ± 0.5	12.1 ± 2.0	N/A	12.8 ± 2.0	12.2 ± 1.8	N/A	12.2 ± 1.8	13.3 ± 1.9	N/A	13.0 ± 1.6
AST, IU/L	9.8 ± 0.8	N/A	10.2 ± 0.9	9.3 ± 1.0	N/A	9.2 ± 0.9	9.9 ± 1.0	N/A	9.9 ± 0.9	10.6 ± 2.0	N/A	10.4 ± 1.8	10.7 ± 1.9	N/A	10.6 ± 1.7	11.1 ± 1.6	N/A	11.5 ± 1.4
AP, IU/L	11.5 ± 1.3	N/A	11.9 ± 1.2	11.8 ± 0.9	N/A	11.6 ± 0.9	11.4 ± 0.9	N/A	11.2 ± 0.8	15.5 ± 2.2	N/A	15.4 ± 2.3	15.2 ± 2.0	N/A	15.0 ± 1.9	15.6 ± 1.7	N/A	15.4 ± 1.7
Bilirubin, mg/dL	0.5 ± 0.02	N/A	0.6 ± 0.02	0.6 ± 0.02	N/A	0.6 ± 0.02	0.6 ± 0.04	N/A	0.6 ± 0.02	0.6 ± 0.02	N/A	0.5 ± 0.02	0.6 ± 0.02	N/A	0.6 ± 0.02	0.5 ± 0.02	N/A	0.6 ± 0.02

Patient data and serum parameters were tabulated on the table. Mean arterial pressure was calculated as (2 × diastolic + systolic) /3. ALT: alanine aminotransferase; AP: alkaline phosphatase; AST: aspartate aminotransferase; BMI: body mass index; DBP: diastolic blood pressure; SBP: systolic blood pressure; HR: heart rate; MAP: mean arterial pressure; N/A: not available.